{"id":"W2075090387","doi":"10.1053/j.gastro.2008.07.014","title":"A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease","year":2008,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":746,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; London Health Sciences Centre","funders":"National Center for Research Resources; Medical Center, University of Pittsburgh; Vanderbilt University Medical Center; McMaster University; University of Pittsburgh; Cleveland Clinic Foundation; Kaiser Permanente; University of Wisconsin-Madison; Cleveland Clinic; Vanderbilt University","keywords":"Ustekinumab; Crohn's disease; Medicine; Monoclonal antibody; Randomized controlled trial; Monoclonal; Internal medicine; Gastroenterology; Disease; Interleukin 23; Immunology; Antibody; Interleukin; Cytokine; Infliximab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007392290025929885,"score_gpt":0.2343504618381705,"score_spread":0.2269581718122406,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}